Rahul Kakkar, John Finn, and Jorge Conde discuss PASTE, a genome editing technique that could make cell therapy more accessible. They explore advancements in genomic medicine, CRISPR technology, and focus on genetic diseases of the liver and autoimmune diseases. They also touch on challenges in transitioning from research to patients and share anecdotes about facial hair.
Using the PASTE technology, Tome Bio Sciences aims to make cell therapy more accessible, scalable, and transform it from a niche product to a discovery platform.
Tome's PAST technology allows for the precise insertion of any sequence of DNA code in any location, revolutionizing the treatment of genetic diseases and enabling rapid iteration and scale in cell therapy.
Deep dives
TOM: A Powerful Genome Editing Technique
Rahul Kukar, CEO of Tone Bio Sciences, and John Finn, CSO, discuss the technology behind TOM, known as PAST, a combination of two older technologies. PAST utilizes a Cas9 Nikkez with an RT enzyme to programably write a landing site for a specific integrase protein, allowing the precise insertion of DNA code. This technology has the potential to make cell therapy more accessible and scalable, transforming it from a niche product to a discovery platform.
The Evolution of Genomic Medicine
John Finn reflects on the progression of genomic medicine over the past decade, from the first publications on CRISPR to the development of cutting-edge tools like base editors. He describes TOM as the missing tool in the genomic editing toolbox, allowing for the insertion of any sequence of code in any location. This advancement opens up new possibilities for treating genetic diseases and has the potential to revolutionize cell therapy, enabling rapid iteration and scale.
The Promise of Programmable Genomic Integration
Rahul Kukar explains why he was drawn to genomic medicine and the potential societal impact it can have. He describes the innovation behind PAST, which combines a Cas9 Nikkez with an RT enzyme to programably write a landing site for integrase proteins. This technology allows for the precise insertion of large pieces of DNA in specific locations without the need to break DNA, offering the ability to fix broken genes and create a single drug to address multiple mutations. It also paves the way for a future where cell therapy becomes a mature discovery platform.
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode